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The TNF superfamily member TWEAK (TNFSF12) is a multifunctional cytokine implicated
in physiological tissue regeneration and wound repair. TWEAK is initially synthesized as
a membrane-anchored protein, but furin cleavage within the stalk region can generate
a secreted TWEAK isoform. Both TWEAK isoforms bind to a small cell surface receptor
named Fn14 (TNFRSF12A) and this interaction stimulates various cellular responses, includ-
ing proliferation and migration. Fn14, like other members of the TNF receptor superfamily,
is not a ligand-activated protein kinase. Instead,TWEAK:Fn14 engagement promotes Fn14
association with members of theTNFR associated factor family of adapter proteins, which
triggers activation of various signaling pathways, including the classical and alternative NF-
κB pathways. Numerous studies have revealed that Fn14 gene expression is significantly
elevated in injured tissues and in most solid tumor types. Also, sustained Fn14 signaling
has been implicated in the pathogenesis of cerebral ischemia, chronic inflammatory dis-
eases, and cancer. Accordingly, several groups are developing TWEAK- or Fn14-targeted
agents for possible therapeutic use in patients. These agents include monoclonal antibod-
ies, fusion proteins, and immunotoxins. In this article, we provide an overview of some of
the TWEAK/Fn14 axis-targeted agents currently in pre-clinical animal studies or in human
clinical trials and discuss two other potential approaches to target this intriguing signaling
node.
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INTRODUCTION
The TNF superfamily member TWEAK was first described in 1997
(1), and since that initial publication dozens of research groups
throughout the world have studied the biological properties of
this multifunctional cytokine. One of the major early milestones in
the TWEAK research arena was the cloning of the human TWEAK
receptor by Wiley et al. (2), which had 100% predicted sequence
identity to a previously reported growth factor-inducible type I
transmembrane protein named Fn14 (3, 4). TWEAK is the only
TNF superfamily member that can bind Fn14 (5). The TWEAK
and Fn14 genes are expressed at low levels in most normal tis-
sues but upregulated in damaged tissue [reviewed in Ref. (6, 7)].
Moreover, the Fn14 gene is highly expressed in both primary
tumors (8–14) and tumor metastases (11). TWEAK is synthe-
sized as a type II transmembrane protein but it can be cleaved to
generate a soluble cytokine (1, 15, 16). TWEAK:Fn14 engagement
promotes TNFR associated factor (TRAF) binding to the Fn14
cytoplasmic tail (17), activation of downstream signaling pathways
(e.g., NF-κB, MAPK, PI3K/Akt), and triggering of various cellular
responses, including proliferation, survival, migration, differenti-
ation, or death [reviewed in Ref. (6, 7)]. Interestingly, binding of
the membrane-bound and soluble TWEAK isoforms to Fn14 can
trigger differential downstream outputs; for example, membrane
TWEAK is a more potent activator of the classical NF-κB signaling
pathway (16).
One important aspect of Fn14 biology that may have clinical
implications is the concept of TWEAK-independent Fn14 sig-
naling. Experimental manipulation of Fn14 expression levels in
cancer cells cultured in vitro can regulate signal transduction and
cellular properties; for example, cell migration and invasion (8, 10,
18–20). These findings have led our group to propose that when
Fn14 expression in cells reaches a certain threshold level it may
signal on its own, even without ligand engagement (6). Recent
studies in which we transiently expressed a mutant Fn14 protein
that is unable to bind TWEAK support the notion that Fn14 can
in fact signal in a ligand-independent manner (21). This signal-
ing mechanism may be particularly important in injured tissues
and cancers where Fn14 levels are high but TWEAK levels are low
[e.g., in glioblastomas (22) and melanomas (unpublished data)].
We hypothesize that the most likely explanation for TWEAK-
independent Fn14 activation is that when Fn14 is expressed at high
levels in cells it spontaneously multimerizes, and this will trigger
TRAF association, downstream signaling, and cellular responses.
A second critical milestone in the TWEAK-Fn14 research arena
was the generation of TWEAK- or Fn14-deficient mice by groups
at Genentech (23) and Biogen Idec (24, 25). Studies using these
mice, in conjunction with studies testing the effects of TWEAK-
neutralizing biologics in mouse models of human tissue injury
and disease, have been instrumental in establishing the gener-
ally accepted view that TWEAK/Fn14 signaling is important for
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effective wound repair following acute tissue injury and that
chronic Fn14 signaling can promote pathological tissue responses
[reviewed in Ref. (6, 7, 26, 27)].
Basic science studies using cells in culture, expression profiling
studies using normal and diseased tissue specimens, and in vivo
studies using wild-type (WT) or genetically engineered mice have
all indicated that the TWEAK/Fn14 axis may play an important
role in the pathophysiology of several different human diseases
[reviewed in Ref. (6, 7, 26–28)]. In general, this axis seems to be
primarily involved in disease progression and maintenance, not
initiation. Numerous academic and industrial research laborato-
ries have initiated programs to develop biologics or small molecule
compounds that activate or inhibit this signaling axis, depend-
ing on the disease target [reviewed in Ref. (28)]. Remarkably, the
first two TWEAK/Fn14 axis-targeted Phase I clinical trials began
recruiting in 2008, only 7 years after the initial report demonstrat-
ing that TWEAK and Fn14 were a ligand-receptor pair (2). In
this article, we provide an overview of some of the TWEAK- or
Fn14-directed therapeutic agents that are presently in pre-clinical
development or have entered clinical trials.
TWEAK/Fn14 AXIS-TARGETED THERAPEUTICS:
INFLAMMATORY AND/OR NEURODEGENERATIVE DISEASES
Inflammation is a complex, dynamic process that occurs in tis-
sues following traumatic, infectious, toxic, or autoimmune injury
[reviewed in Ref. (29, 30)]. This physiologic response is critical for
our ability to heal wounds and fight off pathogens. Inflammation is
normally very tightly controlled but when this process is excessive
or prolonged it contributes to the pathogenesis of numerous
diseases, including atherosclerosis, ischemic stroke, rheumatoid
arthritis (RA), and inflammatory bowel diseases [reviewed in Ref.
(30–32)]. Persistent TWEAK/Fn14 signaling has been implicated
in the pathogenesis of these and other related diseases [reviewed
in Ref. (7, 27)] and in this section we summarize some of the
TWEAK-targeted therapeutic agents under development for these
conditions (Table 1).
Fn14-Fc FUSION PROTEIN
Ischemic stroke ranks third among the most common causes
of mortality and is a leading cause of long-term disability in
the world (33, 34). The onset of cerebral ischemia triggers a
number of pathophysiological events, including oxidative stress,
glucose deprivation, disruption of the architecture of the neu-
rovascular unit [which results in an increase in the permeability
of the blood brain barrier (BBB) and the development of cere-
bral edema], and brain inflammation [reviewed in Ref. (32, 34)].
Intravenous administration of the thrombolytic agent tissue plas-
minogen activator (tPA) within 3–4.5 h of stroke onset is the only
FDA-approved treatment for stroke patients (34).
Numerous studies have indicated that TWEAK is a potential
novel therapeutic target for treatment of acute cerebral ischemia.
Both TWEAK and Fn14 expression have been detected in astro-
cytes, microglia, endothelial cells, and neurons in vitro and
in vivo. TWEAK expression is more prominent in astrocytes, and
Fn14 expression is found predominantly in neurons [reviewed in
Ref. (35)]. Early studies using murine models of focal cerebral
ischemia showed that both TWEAK and Fn14 mRNA expression
in ischemic brain tissue increases within hours after an ischemic
insult (36–38). Importantly, there is also an increased level of
these mRNAs in human infarct tissue obtained from deceased
stroke patients and TWEAK levels are elevated in the serum of
stroke patients (39). Functional studies using Fn14-deficient mice
have indicated that TWEAK/Fn14 signaling contributes to the cell
death and edema that occurs following acute cerebral ischemia
(38, 40). Accordingly, Yepes and colleagues tested whether admin-
istration of a soluble Fn14-Fc decoy protein shortly after ischemia
onset could inhibit TWEAK activity in mouse brain tissue and
thereby attenuate cell death and edema. In their initial studies
they found that Fn14-Fc injection significantly reduced infarct vol-
ume, microglia activation, and apoptotic cell death in the ischemic
penumbra (37). Subsequent research found that Fn14-Fc delivery
could also improve animal motor activity and reduce the extent
of cerebral ischemia-triggered BBB breakdown and edema (40,
41). Thus, TWEAK neutralization may be an effective therapeutic
strategy for acute cerebral ischemia.
Fn14-TRAIL FUSION PROTEIN
Multiple sclerosis (MS) is an immune-mediated disease of the cen-
tral nervous system (CNS) that causes progressive neurological
deterioration [reviewed in Ref. (42, 43)]. MS is characterized by
Table 1 | Examples ofTWEAK-targeted therapeutic agents for inflammatory and/or neurodegenerative diseases.
Agent Developer Type of agent Status Disease Reference(s)
Fn14-Fc EUSOM/UMSOM Decoy receptor Pre-clinical Cerebral ischemia and edema (stroke) (37, 40, 41)
Fn14-TRAIL
(KAHR-101)
KAHR Medical Signal converter
protein
Pre-clinical EAE (model of multiple sclerosis) (52, 54)
BIIB023 Biogen Idec Neutralizing mAb Phase I trial Rheumatoid arthritis ClinicalTrials.gov
Start date: October 2008 NCT00771329
Completion date: April 2011 (68)
BIIB023 Biogen Idec Neutralizing mAb Phase II trial Lupus nephritis ClinicalTrials.gov
Start date: July 2012 (recruiting) NCT01499355
EUSOM, Emory University School of Medicine; UMSOM, University of Maryland School of Medicine; EAE, experimental autoimmune encephalomyelitis; mAb,
monoclonal antibody.
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the presence of focal demyelinated lesions in the white and gray
brain matter, the accumulation of inflammatory cells, and BBB
disruption with edema. A number of effective anti-inflammatory
and immunomodulatory treatments are now available that reduce
disease activity for patients in the relapsing-remitting stage of
the disease [reviewed in Ref. (43, 44)]. The primary first-line
treatments for MS are interferon-β (IFN-β) glatiramer acetate
(Copaxone), a synthetic protein whose mechanism of action is not
fully understood. Over time, however, autoantibodies can develop
in the IFN-β-treated patients, resulting in decreased efficacy. Skin
conditions such as erythema were the most common side effects
in Copaxone-treated patients [reviewed in Ref. (43)]. If disease
stabilization fails to be achieved using these first-line therapies,
a number of second-line treatments are available. These second-
line treatments leave MS patients at risk for a number of side
effects including CNS infection, skin cancer, and cardiac toxic-
ity [reviewed in Ref. (43)]. Therefore, new targeted therapies are
needed for MS patients and several studies have indicated that
TWEAK deserves consideration as a potential molecular target
[reviewed in Ref. (45)].
Experimental autoimmune encephalitis (EAE) is a Th1-
mediated autoimmune disease of the CNS that is the most com-
monly used experimental model for human CNS demyelinating
diseases, including MS [reviewed in Ref. (43, 46)]. EAE is induced
by inoculating mice with myelin oligodendrocyte glycoprotein
(MOG). This leads to a disease course characterized by an acute
paralytic phase followed by a moderate remission and finally a
chronic phase associated with demyelination. Two independent
studies showed that TWEAK/Fn14 pathway inhibition decreased
disease severity in the EAE model. In one study, Desplet-Jego et al.
found that intraperitoneal administration of an anti-TWEAK-
neutralizing monoclonal antibody (mAb) after the priming phase
reduced leukocyte CNS infiltration and clinical score (47). In the
second study, Mueller et al. showed that intraperitoneal injection
of recombinant rat soluble TWEAK and Fn14 extracellular domain
resulted in induction of neutralizing antibodies, causing a decrease
in CNS inflammatory infiltration and EAE severity in both rat
and mouse models (48). It has also been reported that soluble
TWEAK overexpression, accomplished either by injection of a
TWEAK expression plasmid (48) or the generation of TWEAK
transgenic mice (49), increases EAE severity.
Another animal model relevant to MS is cuprizone-induced
demyelination. It is an ideal system to study neuroinflammation,
demyelination, and remyelination [reviewed in Ref. (46)]. Cupri-
zone is a copper chelating agent, which causes oligodendrocyte
cell death and microglial infiltration into the damaged site in the
murine CNS. Whereas in the EAE model demyelination is depen-
dent upon CD4+ T cells, demyelination in the cuprizone model
is mediated by microglia with little contribution from peripheral
macrophages. Iocca et al. showed that modest upregulation of
Fn14 and TWEAK occurred during the demyelination phase of
cuprizone treatment (50). Furthermore, TWEAK-deficient mice
exhibited a delay in demyelination of the corpus callosum after
4 weeks of cuprizone treatment as compared to WT animals.
These studies, in combination with research demonstrating
that TWEAK and Fn14 expression is upregulated in human brain
specimens from MS patients compared to controls (51) support
the contention that TWEAK-neutralizing agents could be effective
therapeutics for this disease. In this regard, Razmara et al. reported
that transposon-mediated expression of an Fn14-TRAIL fusion
protein in mice reduced the incidence and severity of EAE (52).
Fn14-TRAIL consists of the Fn14 extracellular domain fused to the
soluble form of the TNF superfamily member TRAIL. This “signal
converter protein” is designed to both inhibit TWEAK/Fn14 sig-
naling and promote TRAIL/TRAILR signaling, with this second
functional attribute included on the basis of earlier work showing
that TRAIL attenuates MOG-induced EAE (53). A more recent
study by Prinz-Hadad et al. found that purified Fn14-TRAIL pro-
tein limited T cell responses and alleviated EAE severity only when
administered 10 days after EAE induction as compared to Fn14-
TRAIL treatment starting on the day of MOG immunization (54).
This suggests that Fn14-TRAIL has a more significant impact on
the propagation phase of EAE rather than during the induction
phase. Fn14-TRAIL (KAHR-101) is currently under further pre-
clinical development by KAHR Medical Ltd., for MS and cancer
(see below).
TWEAK mAb BIIB023
Rheumatoid arthritis is a progressive autoimmune disease char-
acterized by joint inflammation and tissue destruction that leads
to disability and a decrease in quality of life. While the cause of
RA is unknown, many genetic determinants and environmental
factors that contribute to disease susceptibility have been iden-
tified [reviewed in Ref. (55, 56)] and the pathogenesis of the
disease has been well characterized [reviewed in Ref. (57)]. RA
development involves a cellular and humoral immune response to
auto-antigens, with patients developing a range of autoantibodies
[reviewed in Ref. (58)]. The disease is usually concentrated in the
joint regions of the hands, knees, or feet, where the inflamed syn-
ovial membrane, caused by activated leukocytes and angiogenesis,
contains hyperplastic synoviocytes, pro-inflammatory cytokines,
cartilage-degrading enzymes, and the osteoclast-containing pan-
nus that breaks down bone. RA treatment options include cor-
ticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs),
and disease-modifying anti-rheumatic drugs (DMARDs) such
as methotrexate (MTX) and biologics including TNF-α or IL-6
inhibitors [reviewed in Ref. (57, 59)].
Numerous studies have implicated the TWEAK/Fn14 axis as
a potential contributor to RA pathophysiology. When TWEAK
and Fn14 expression were evaluated by immunohistochemistry
of synovial tissue (ST) biopsies, TWEAK expression was higher
in patients with RA compared to patients with psoriatic arthri-
tis (PsA) (60) or osteoarthritis (OA) (61, 62). TWEAK levels
are higher in serum obtained from RA patients versus control
(63) and in both serum and synovial fluid of RA versus OA
patients (62, 64). Furthermore, TWEAK expression was detected
in newly diagnosed, DMARDs-naive patients as well as TNF-α
mAb (Infliximab)-treated patients (60). While Fn14 expression
was found elevated in RA patients compared to normal, healthy
controls (62) there was no increase relative to PsA patients and
no difference between active and inactive RA (60). Co-staining
experiments revealed that TWEAK expression was found on
fibroblast-like synoviocytes, CD22+ B cells, macrophages, plasma
cells, multi-nucleated cells, and ST blood vessels (60, 62). In vitro
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studies have shown that TWEAK may contribute to RA patho-
genesis through multiple mechanisms such as promoting bone
resorption (61, 62) and joint tissue destruction (65), inhibiting
bone and cartilage repair mechanisms (65), and promoting joint
inflammation (66).
In vivo studies using mouse models of RA have shown that the
TWEAK/Fn14 signaling pathway is a significant contributor to RA
pathogenesis. An initial report showed that TWEAK levels were
elevated in the sera of mice with collagen-induced arthritis (CIA)
and that the disease severity, assessed by evaluating inflammation
in the mouse paws, was decreased when the mice were treated
with an anti-TWEAK-neutralizing mAb (65). The TWEAK anti-
body treatment also resulted in reduced inflammation and reduced
cartilage and bone loss according to histological analysis. Further-
more, the TWEAK antibody-treated mice had reduced synovial
angiogenesis and a reduction in the serum levels of inflamma-
tory cytokines and chemokines. A second independent study also
showed that an anti-TWEAK-neutralizing mAb attenuated the
severity of CIA by reducing synovial angiogenesis and inflam-
matory chemokine levels in the serum and joints of CIA mice
(67). Both studies showed that T- and B-cell responses to colla-
gen II were maintained in the CIA experimental animals that were
treated with TWEAK antibody, indicating that TWEAK/Fn14 sig-
naling blockade does not have an effect on the adaptive immune
response.
Recently, the results of a Phase I clinical trial (ClinicalTri-
als.gov Identifier NCT00771329) testing the TWEAK-blocking
mAb BIIB023 in patients with RA were reported by Wisniacki
et al. (68). BIIB023 was well tolerated in RA patients that received
a single dose up to 20 mg/kg either alone or as an add-on to TNF-
α inhibitor administration, with all patients taking background
MTX. The single BIIB023 dose did not increase the incidence of
adverse events when added to the TNF inhibitor treatment, and all
adverse effects (AEs) were mild to moderate in severity. Addition-
ally, there were no serious infections in this trial, consistent with
the idea that blocking TWEAK/Fn14 signaling does not inhibit
the adaptive immune response. BIIB023 showed low immuno-
genicity, favorable pharmacokinetics, and at high doses, was able
to suppress serum soluble TWEAK levels for 28 days. BIIB023 is
currently under investigation in a Phase II trial in patients with
lupus nephritis (LN) (see below).
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease with a relapsing-remitting course and a diverse array of
clinical manifestations, including LN, cutaneous lupus, neuropsy-
chiatric lupus, and atherosclerosis, that contribute to a decrease
in quality of life and an increase in mortality [reviewed in Ref.
(69)]. SLE genetic risk factors and disease pathogenesis have been
well studied [reviewed in Ref. (70)]. SLE patients develop antibod-
ies against an array of auto-antigens, including nuclear antigens,
which can lead to inflammation and injury in many organs. SLE is
primarily treated with glucocorticoids, cyclophosphamide, B cell-
targeted therapy (e.g., anti-CD20 mAbs), and immunosuppressive
drugs that are associated with a risk of infection, adverse events
such as infusion reactions (characterized by fever, chills, rash, and
swelling), and organ damage. These serious side effects have lead
more recently to the development of targeted, biologic therapies
[reviewed in Ref. (59)], but biologic and traditional therapies
for SLE are not always effective and there is still a need for the
development of novel, targeted therapies.
The TWEAK/Fn14 signaling pathway has been identified as a
potential therapeutic target for LN because of its role in promot-
ing inflammation, angiogenesis, cell proliferation, and fibrosis: all
biological processes that contribute to LN pathology [reviewed in
Ref. (71)]. TWEAK expression has been examined in clinical speci-
mens and while there have been conflicting reports about TWEAK
mRNA and protein levels in the peripheral blood mononuclear
cells and serum of SLE patients (72–75), there have been consis-
tent reports of elevated TWEAK levels in the kidney and urine of
LN patients (73, 76–78). The urinary TWEAK levels in LN patients
were found to be increased relative to healthy control donors, SLE
patients without LN, RA patients, OA patients, and patients with
kidney disease due to diabetes or hypertension. These data sug-
gest that increased urinary TWEAK levels are due to the specific
pathology of LN, and not due to a non-specific effect of systemic
autoimmunity or decreased kidney function.
Animal studies also support the idea that TWEAK is involved in
the local kidney pathology seen in LN. In a chronic graft-versus-
host (cGVH) mouse model of SLE, splenocytes are transferred
from a donor mouse strain with an MHC class II mutation into
a coisogenic recipient mouse. This results in the activation of
the alloreactive donor T cells, which in turn costimulate recip-
ient B cells and promote the production of autoantibodies and
subsequent kidney damage. When SLE was induced in Fn14-
deficient mice, there was a reduction in renal disease as measured
by glomerular IgG deposition and urinary protein levels (pro-
teinuria) compared to SLE-induced WT mice (79). There was
also a reduction in pro-inflammatory cytokines and chemokines,
a decrease in kidney-infiltrating macrophages, and a decrease in
renal cellular proliferation. There were no differences in serum IgG
levels or serum autoantibody levels between the Fn14-deficient
and WT mice, indicating that TWEAK/Fn14 signaling does not
play a role in the induction of SLE. When a murine neutralizing
anti-TWEAK antibody was used in the same SLE mouse model, a
similar reduction in renal disease was observed (79).
In another study using bone marrow chimeric mice, the rela-
tive contributions of Fn14 expression in the resident kidney cells
and bone marrow in the development of LN were evaluated using
the cGVH mouse model of SLE (80). Mice with Fn14+ non-bone
marrow-derived cells, mice with the Fn14+ bone marrow-derived
cells, and control non-chimeric cGVH mice displayed the same
elevation in serum antinuclear autoantibodies. In contrast, the
mice with Fn14+ non-bone marrow-derived cells showed a more
rapid and stronger nephritis disease course than mice with Fn14+
bone marrow-derived cells, as measured by urine albumin lev-
els. These results indicate that Fn14 expression does not impact
SLE induction, but that resident kidney cells, and not the bone
marrow-derived cells, play a prominent role in LN pathology.
Another model of LN, nephrotoxic nephritis (NTN), was used
to evaluate the role of TWEAK and Fn14 in LN pathology (81).
NTN is induced by passive transfer of preformed rabbit anti-
mouse glomerular antibodies into mice pre-immunized with rab-
bit IgG, which promotes the deposition of immune complexes
and macrophage-mediated injury in the kidney. Fn14-deficient
mice with NTN developed reduced renal disease compared to WT
Frontiers in Immunology | Inflammation December 2013 | Volume 4 | Article 473 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cheng et al. TWEAK/Fn14 axis-targeted therapeutics
mice. Similarly, when NTN was induced in WT mice treated with
anti-TWEAK antibody, the mice displayed decreased proteinuria
and improved kidney pathology, including a decrease in glomeru-
lar proliferation. Additionally, TWEAK antibody-treated mice had
decreased mRNA levels of pro-inflammatory mediators, reduced
levels of glomerular immune complex deposition, less fibrosis, and
less macrophage infiltration of kidneys.
The TWEAK/Fn14 pathway was also shown to promote the
neuropsychiatric symptoms of SLE in an MRL lymphoprolifera-
tive (lpr) mouse strain that contains a mutation in the Fas gene
that results in the spontaneous development of SLE (82). TWEAK
and Fn14 mRNA expression were upregulated in the brains of
MRL/lpr mice compared to MRL mice and Fn14 protein expres-
sion was mostly detected in the endothelial cells. There were no
differences found between Fn14-deficient and WT mice in the
quantity of a range of autoantibodies. Fn14-deficient mice showed
less depression-like behavior in a forced swim test and a saccharin-
drink reward test and improved spatial memory in an object place-
ment test,while there was no difference in motor ability detected by
a balance beam coordination test. The mRNA expression of pro-
inflammatory mediators and RANTES protein expression were
decreased in Fn14-deficient brain compared to WT brain. Fn14-
deficient mice had decreased CSF albumin relative to WT mice,
a measure of BBB integrity. Additionally, anti-dsDNA antibodies,
shown to be similar in serum, were increased in the WT brain
compared to the Fn14-deficient brain. These data indicate that the
TWEAK/Fn14 pathway may promote neuropsychiatric lupus by
compromising the BBB.
The anti-TWEAK mAb BIIB023 is currently being evalu-
ated in a Phase II clinical trial (ClinicalTrials.gov Identifier
NCT01499355) to test its efficacy against LN, which as mentioned
above, is a common manifestation of SLE that can lead to kidney
failure. While the primary endpoint of the trial is to test the renal
response of LN patients to BIIB023, secondary objectives include
assessment of extrarenal SLE disease activity and manifestations
[reviewed in Ref. (71)].
TWEAK/Fn14 AXIS-TARGETED THERAPEUTICS: CANCER
Cancer is the second leading cause of death in the USA, with
~580,000 deaths predicted to occur in 2013 (83). The vast major-
ity of these deaths are due to metastasis, a complex multi-step
process whereby primary tumor cells travel to distant organs and
form secondary tumors that can impair critical organ functions
[reviewed in Ref. (84, 85)]. Significant progress has recently been
made in identifying the molecular genetic abnormalities that drive
the growth and spread of some cancer types, and these find-
ings have led to the development of new targeted therapeutics
that dramatically improve the survival of those patients with
tumors harboring these particular genetic alterations [reviewed
in Ref. (86, 87)]. However, the main treatment options for most
cancer patients with metastatic disease continue to be chemother-
apy and/or radiation therapy. Thus, there is an urgent need
to identify new molecular targets for anti-cancer drug devel-
opment, and in this section we summarize some of the drug
development efforts that target the TWEAK and Fn14 proteins
(Table 2).
Table 2 | Examples ofTWEAK- or Fn14-targeted therapeutic agents for cancer.
Agent Developer Type of agent Target Status Comments Reference
RG7212
(RO5458640)
Hoffmann–La
Roche
Neutralizing mAb TWEAK Phase I trial Various cancer types; only
patients with Fn14+ tumors; no
toxicities noted; disease
stabilization in some patients
ClinicalTrials.gov
NCT01383733 (88, 89)Start date: 2011 July
Completion date:
2013 March
Fn14-TRAIL
(KAHR-101)
KAHR Medical Signal converter
protein
TWEAK Pre-clinical Inhibits tumor growth in
xenograft model
(90)
BIIB036
(P4A8)
Biogen Idec Agonistic mAb Fn14 Pre-clinical Inhibits tumor growth in
xenograft models
(91, 92)
18D1 UHW/arGEN-X Agonistic mAb Fn14 Pre-clinical Inhibits tumor formation in
experimental metastasis assays
(93)
PDL192 (ena-
vatuzumab)
Abbott Agonistic mAb Fn14 Phase I trial Various cancer types; liver and
pancreatic enzyme toxicity
ClinicalTrials.gov
NCT00738764 (9, 12, 94)Start date: 2008 July
Completion date:
2011 October
ITEM4-rGel MD Anderson
Cancer
Center/UMSOM
Immunotoxin
conjugate
Fn14 Pre-clinical All three agents inhibit tumor
growth in xenograft models
(11, 95, 96)
hSGZ Immunotoxin fusion
protein
(11, 96)
GrB-TWEAK Ligand-apoptotic
factor fusion protein
2013 AACR Meeting
Abstract #2185
UHW, University Hospital ofWürzburg; UMSOM, University of Maryland School of Medicine; rGel, recombinant gelonin; GrB, granzyme B; mAb, monoclonal antibody.
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STRATEGY #1: INHIBITION OF TWEAK:Fn14 ENGAGEMENT
TWEAK mAb RG7212
Both TWEAK and Fn14 expression has been detected in tumors
and TWEAK/Fn14 signaling may promote tumor growth in vivo
through a variety of mechanisms [reviewed in Ref. (6, 97) and
see Ref. (2, 8, 10, 20, 98–100)]; accordingly, agents that inhibit
TWEAK binding to Fn14 may have potential therapeutic utility.
In a recent report, Yin et al. described the development, functional
characterization, and anti-cancer properties of a humanized anti-
TWEAK-neutralizing mAb named RG7212 (RO5458640) (88).
This antibody blocks TWEAK-stimulated proliferation, NF-κB
activation, and cytokine secretion when added to cells cultured
in vitro. Also, tumor growth inhibition was demonstrated in
mouse models in which human cancer cell lines or patient-derived
tumorgrafts were xenotransplanted into immunodeficient mice,
or alternatively, when syngeneic mouse cancer cell lines were allo-
transplanted into immunocompetent mice. The greatest tumor
growth inhibition was detected in xenograft models of renal cell
carcinoma (ACHN, Caki-1), breast carcinoma (MDA-MB-231),
and non-small cell lung cancer (Calu-3). TWEAK mAb-treated
mice had decreased tumor mRNA levels of various TWEAK-
inducible genes and decreased serum levels of mouse (m) MMP9,
(m) EGF, (m) bFGF, human (h) CCL2, (h) IL-8, and (h) IL-
6. Western blot and immunohistochemistry analyses of tumor
tissue showed that TWEAK mAb-treated mice had decreased
cell proliferation and increased apoptotic signaling. Depletion
of specific immune cells in a syngeneic mouse model showed
that CD8+ T cells and NK cells, but not CD4+ T cells, were
required for RG7212-mediated tumor growth inhibition. Taken
together, these data demonstrate that TWEAK/Fn14 signaling sup-
ports tumor growth by promoting cell proliferation and survival
and also by shaping the tumor microenvironment by stimulat-
ing the expression of chemokines, cytokines, and inflammatory
mediators.
In consideration of the RG7212 pre-clinical data summarized
above, a Phase I trial was initiated in 2011 July (ClinicalTrials.gov
Identifier NCT01383733). Thirty-eight patients with Fn14-
positive tumors were treated with RG7212 (89). No dose-limiting
toxicities were observed and most adverse events were consid-
ered low-grade. One patient with refractory melanoma showed
tumor regression, while another eight patients, including patients
with refractory non-small cell lung cancer, renal cell carcinoma,
mesothelioma, and metastatic breast cancer, had stable disease for
over 3 months. Thus, RG7212 demonstrated tolerability and some
efficacy in patients with advanced solid tumors.
Fn14-TRAIL fusion protein
The Fn14-TRAIL protein described above in the context of MS has
recently been shown to induce hepatocellular carcinoma (HCC)
cell apoptosis in vitro in a dose-dependent manner (90). In con-
trast, the fusion protein did not have a significant impact on
cell viability in non-malignant hepatocyte cell lines. Interestingly,
HCC cells treated with Fn14-TRAIL underwent higher rates of
apoptosis than when treated with soluble TRAIL or soluble Fn14
extracellular domain either alone or in combination. Furthermore,
subcutaneous administration of Fn14-TRAIL significantly inhib-
ited HCC xenograft growth in vivo (90). It is unclear at his time
whether TWEAK neutralization is contributing to the anti-tumor
effects noted with this agent.
Comments on strategy #1
The main concern with this strategy is that TWEAK is expressed
at low levels in many Fn14-overexpressing tumors and in this situ-
ation it is likely that TWEAK-independent Fn14 signaling occurs,
which will not be inhibited by these agents.
STRATEGY #2: ACTIVATION OF THE Fn14 SIGNALING PATHWAY
Fn14 mAbs BIIB036, 18D1, and PDL192
Fn14 gene expression is elevated in over a dozen different solid
tumor types compared with matched adjacent normal tissue or
normal tissues from non-diseased donors (8–14); consequently,
Fn14 is also a potential target for cancer therapy. TWEAK is a pro-
apoptotic factor for some human cancer cell lines [reviewed in Ref.
(6,101)] and several studies have revealed that TWEAK-stimulated
cell death occurs via an indirect mechanism; in particular, via
TWEAK-triggered upregulation of other cytokines [e.g., TNF-α
(102–105) and IFN-β (106)]. The ability of TWEAK to promote
tumor cell death has provided the rationale for several groups to
explore the potential of agonistic Fn14 mAbs as anti-cancer thera-
peutics. Scientists at Biogen Idec have developed a humanized anti-
Fn14 antibody named BIIB036 (P4A8) that binds with high affinity
to Fn14 in BiaCore and FACS assays (91). BIIB036 treatment
of Fn14+ human cancer cell lines activated the NF-κB signaling
pathway, stimulated IL-8 production, and in some cases induced
cell death, indicating that this mAb exhibits agonistic activity.
This mAb can also inhibit the binding of both membrane-bound
and soluble TWEAK to Fn14 (91, 107). Intraperitoneal injection
of BIIB036 inhibited WiDr colon carcinoma, NCI-N87 gastric
carcinoma, MDA-MB-231 breast cancer, and patient-derived col-
orectal tumor cell growth in xenograft assays (91, 92). Subsequent
studies indicated that the optimal dosing for BIIB036 in tumor-
bearing mice was twice weekly and tumor growth inhibition per-
sisted up to 50 days after the termination of dosing (92). Finally,
BIIB036 exhibited antibody-dependent cell-mediated cytotoxicity
(ADCC) in vitro and maximal BIIB036 anti-tumor activity in vivo
required full Fc effector function, indicating that ADCC was one
of the mechanisms mediating the observed inhibitory effects (91).
BIIB036, as well as the 18D1 and PDL192 mAbs described below,
exhibits the strongest agonistic activity upon oligomerization with
protein G or binding to Fcγ receptors (93, 107).
Researchers at the University Hospital of Würzburg and
arGEN-X recently reported the generation and characterization
of three llama-derived anti-Fn14 mAbs (93). Two of these mAbs,
18D1 and 4G5, blocked TWEAK:Fn14 binding and all exhibited
agonistic activity (including cell death induction in the presence
of cycloheximide). The 18D1 antibody inhibited metastatic colony
formation in both RENCA cell and HCT116 cell experimen-
tal metastasis assays, and the anti-metastatic effect noted in the
RENCA cell experiments was predominantly mediated via ADCC.
Facet Biotech, which was acquired by Abbott Laboratories in
2010, has also developed an agonistic Fn14 antibody for potential
therapeutic use (9). The murine form of this antibody, 19.2.1, was
shown to inhibit the growth of multiple cancer cell lines in a dose-
dependent manner, including HSC3 oral squamous carcinoma
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cells, A253 salivary gland cells, A375 melanoma cells, and Mia-
PaCa2 pancreatic cells. Its humanized counterpart, PDL192 (Ena-
vatuzumab), also exhibited growth inhibitory activity in vitro (9).
Studies using HER2+ SKBR3 breast cancer cells revealed that
PDL192 had a synergistic effect on growth inhibition when com-
bined with trastuzumab (Herceptin), the standard treatment for
HER2+ breast cancer patients (12). PDL192 also exhibited anti-
tumor activity in multiple xenograft models of breast cancer,
including the MCF-7, HCC70, and MDA-MB-231 models (12).
However, the antibody had little to no effect on the in vivo growth
of other Fn14+ cell lines, including Calu6 lung cancer cells and
HCT116 colorectal cancer cells (9). As found for BIIB036, the
observed growth inhibitory effects of PDL192 on xenograft tumor
growth in mice are mediated, at least in part, by ADCC (9). In
contrast to BIIB036 and 18D1, PDL192 does not recognize murine
Fn14 and does not interfere with TWEAK:Fn14 binding (93, 107).
Abbott Laboratories initiated a Phase I clinical trial in 2008 July to
test the effects of PDL192 administration (six dosage levels) in 30
patients with advanced solid tumors (ClinicalTrials.gov Identifier
NCT00738764). The trial was completed in 2011 October and the
results were disclosed in Abstract form at an international meeting
(94). No patients showed partial or complete tumor regression but
two patients had stable disease for 2–4 months duration. However,
patients treated with PDL192 at doses demonstrating anti-tumor
efficacy in mice had elevated liver and pancreatic enzyme levels,
indicating significant drug toxicity in these organs.
Comments on strategy #2
Monoclonal antibodies that target specific cell surface receptors on
tumor cells may attenuate tumor growth in vivo via multiple mech-
anisms, including receptor activation, blockade of ligand:receptor
engagement,and stimulation of immune cell Fc receptor-mediated
pathways such as ADCC. All three of the Fn14-specific mAbs
described above have complex biological properties when charac-
terized in vitro (93, 107) and thus the precise mechanisms respon-
sible for their apparent anti-tumor growth (PDL192, BIIB036)
and anti-metastatic (18D1) activity is not clear. The main con-
cern with the use of Fn14 mAbs that may exhibit agonistic activity
within the tumor milieu is that Fn14 activation in most “normal”
and cancer cell lines does not cause cell death. Indeed, Yin et al.
found that TWEAK treatment had no effect on the viability of 299
tumor cell lines as assessed by CellTiter-Glo or MTT assays (88).
In general, most studies support the view that TWEAK/Fn14 sig-
naling in the tumor microenvironment will most likely stimulate
pro-tumorigenic/metastatic cellular responses, including tumor
cell growth (88, 108), invasion (8, 10, 18–20), and resistance
to chemotherapeutic agents (109). There is also evidence that
TWEAK can act on Fn14+ endothelial cells and promote angio-
genesis (2, 100, 110); thus, if TWEAK is expressed by tumor cells or
tumor-associated stromal/immune cells in vivo it could promote
tumor vascularization. Agonistic Fn14 mAbs could have a similar
biological effect.
STRATEGY #3: DIRECT KILLING OF Fn14-POSITIVE CANCER CELLS
Fn14 mAb-based immunotoxins
Targeted toxins are a class of cancer therapeutics that internal-
ize into malignant cells to deliver a cytotoxic payload. These
agents consist of a targeting polypeptide (e.g., an antibody,
an antibody fragment, or a receptor ligand) that is either
chemically conjugated or covalently linked to a toxin, which
is usually of bacterial or plant origin [reviewed in Ref. (111,
112)]. Targeted toxins that utilize a mAb or the variable frag-
ment (Fv) of an antibody as the targeting moiety are gen-
erally referred to as immunotoxins. Typically, targeted tox-
ins bind specific cell surface receptors, become internalized
via receptor-mediated endocytosis, and then the toxin moi-
ety is eventually delivered to the cytosol, its site of action.
Immunotoxins targeting a variety of cell surface proteins are
currently being evaluated in human clinical trials [reviewed in
Ref. (112)].
Two types of Fn14-targeted immunotoxins have been devel-
oped and tested in pre-clinical cancer studies by Rosenblum and
colleagues (11, 95, 96). Both agents are based on the anti-Fn14
antibody ITEM4 and the plant toxin gelonin. ITEM4 was raised
against the human Fn14 extracellular domain (113). It binds
both human and murine Fn14 and has weak agonistic activity
(11, 113, 114). Gelonin is a ~29-kDa N -glycosidase found in
the seeds of Gelonium multiflorum plants that cleaves 28S rRNA
and thereby inhibits protein synthesis (115). The first immuno-
toxin, ITEM4-rGel, was composed of the ITEM4 mAb chemically
conjugated to a recombinant form of gelonin (rGel) purified
from E. coli cells. This agent was highly cytotoxic when added
to Fn14+ cancer cell lines in vitro and inhibited human T-24,
MDA-MB-435, and MDA-MB-231 cancer cell growth in xenograft
assays after intravenous administration (11, 95, 96). The second
immunotoxin was a humanized, bivalent single-chain protein
named hSGZ. The N-terminal region of this protein consists of
a single-chain Fv (scFv) fragment of ITEM4 in which the V H
and V L sequences from the hypervariable region were linked by
a flexible peptide. These two domains were “humanized” by site-
specific mutagenesis to alter certain amino acid residues within the
framework domain without impacting affinity or specificity. The
C-terminal region consists of rGel followed by a short dimeriza-
tion domain to produce a bivalent immunotoxin. Recombinant
hSGZ protein purified from E. coli cells is also highly cytotoxic
to Fn14+ cells in vitro and therapeutic efficacy studies showed
significant growth inhibition in both MDA-MB-435 melanoma
and MDA-MB-231 breast cancer xenograft models (11, 96). No
overt toxicity was noted in mice treated with either the ITEM4-
rGel or hSGZ immunotoxins, although as mentioned above,
ITEM4 can bind murine Fn14 (114). Thus, these two immuno-
toxins appear to be effective anti-cancer agents in pre-clinical
studies.
Granzyme B-TWEAK fusion protein
A completely human fusion protein designed to kill Fn14+ can-
cer cells was recently described by Zhou et al. (96) at the 2013
AACR Annual Meeting (Abstract #2185). This construct, named
granzyme B (GrB)-TWEAK, uses the human TWEAK receptor-
binding domain as the targeting moiety and GrB as the cell-
killing agent. GrB is a serine protease stored in the secretory
granules of cytotoxic T lymphocytes and NK cells [reviewed
in Ref. (116, 117)]. It normally enters target cells (e.g., non-
self or virally infected) via the granule exocytosis pathway and
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promotes apoptotic cell death [reviewed in Ref. (116, 117)].
GrB-TWEAK is expressed in transfected HEK293 cells as a
catalytically inactive protein, purified from conditioned media
using nickel-NTA affinity chromatography, and then activated
by in vitro incubation with enterokinase. Initial studies have
revealed that GrB-TWEAK is rapidly internalized by Fn14+ can-
cer cells and is highly cytotoxic in the low nanomolar range.
Also, GrB-TWEAK administration (iv) inhibited HT-29 colon
carcinoma cell growth in immunodeficient mice (Abstract #2185
Poster).
Comments on strategy #3
Importantly, the therapeutic efficacy of these agents does not
depend on promoting or inhibiting intracellular signaling path-
ways or on immune cell function (i.e., ADCC). Also, since these
agents directly kill cancer cells, vulnerable cells cannot activate
compensatory signaling cascades that promote drug resistance.
Nevertheless, there are a number of obstacles that limit the clin-
ical application of this class of therapeutic agents; for example,
bacterial or plant toxins can cause vascular leak syndrome and
elicit immune responses in patients [reviewed in Ref. (112, 118)].
However, with respect to rGel immunogenicity, in a recent Phase
I trial in which an anti-CD33 mAb-rGel immunoconjugate was
administered to 28 patients with advanced myeloid malignancies,
the immunogenicity of the rGel moiety appeared to be low, as
only 2 patients developed detectable levels of anti-rGel antibodies
during the course of treatment (119).
TWEAK/Fn14 AXIS-TARGETED THERAPEUTICS: ADDITIONAL
APPROACHES
Protein-based therapeutics like those listed in Tables 1 and 2 can
only act on cell surface or secreted molecules, are costly to produce,
and have other inherent disadvantages; for example, they gener-
ally have to be administered intravenously and they have poor
tissue penetration [reviewed in Ref. (120)]. Here, we describe two
additional classes of therapeutic agents that may be suitable for
inhibition of chronic TWEAK/Fn14 signaling in diseased tissue.
RNAi-BASED THERAPEUTICS TO DOWN-REGULATE TWEAK OR Fn14
GENE EXPRESSION
RNA interference (RNAi) is a potent mRNA sequence-specific
post-transcriptional gene silencing mechanism that is currently
being evaluated for use as a therapeutic strategy for a wide range
of human disorders [reviewed in Ref. (121, 122)]. The goal is to
down-regulate the expression of cellular genes involved in disease
by administration of either synthetic small interfering RNAs (siR-
NAs) or gene constructs encoding short hairpin RNAs (shRNAs).
Numerous siRNA/shRNA therapeutics have already advanced into
clinical trials [reviewed in Ref. (123)], but there are still signif-
icant challenges to overcome for safe and effective use of these
agents. Some of these challenges include ineffective delivery into
target cells, the potential for off-target effects, and immune system-
mediated toxicities [reviewed in Ref. (121, 122, 124)]. Although
there have been no reports to date describing TWEAK or Fn14
depletion in vivo after localized or systemic delivery of either
siRNA duplexes or shRNA constructs, this is an approach that
should be considered in the near future as progress continues to
be made on the development of RNAi-based drugs for treatment
of human diseases.
SMALL MOLECULE THERAPEUTICS TO INHIBIT TWEAK
TRIMERIZATION, TWEAK:Fn14 BINDING, Fn14 MULTIMERIZATION, OR
Fn14:TRAF INTERACTION
The classic model of TNF:TNFR superfamily signaling is that the
binding of homotrimeric ligands to receptor monomers promotes
receptor trimerization (and most likely multimerization), which
in turn leads to the recruitment of intracellular adaptor proteins
to the cytoplasmic domains of the receptors. Thus, effective signal
transduction depends on a series of highly specific protein-protein
interactions. Although targeted disruption of protein-protein
interfaces by small organic molecules is generally regarded as a
challenging goal [reviewed in Ref. (125)], there have been some
successes with this approach in the TNF/TNFR superfamily field.
For example, compounds have been identified that bind to trimeric
TNF-α (126) or CD40L (127), thereby causing conformational
perturbations that inhibit receptor binding and functional activ-
ity. Small molecule inhibitors of the TNF-α:TNF-R1 interaction
have also been reported (128).
TWEAK/Fn14 pathway-specific small molecule inhibitors
could potentially be identified using several experimental strate-
gies, including: (i) the use of cell- or recombinant protein-based
high throughput screening assays for testing of synthetic chemical
or natural product libraries, and (ii) computational methods such
as virtual screening using X-ray- or NMR-derived protein struc-
tures and chemical compound databases (in silico drug discovery).
In regard to the first strategy, a high throughput screen measur-
ing the effect of ~60,000 compounds on soluble TWEAK binding
to the Fn14 extracellular domain was conducted by Benicchi and
colleagues (129). Fifteen primary hit compounds were identified
and subsequent counterassays revealed that two were potent but
partial inhibitors and two were weak inhibitors (overall hit rate of
0.007%). However, the inhibitory activity of these molecules was
not confirmed using other types of assays, and experiments were
not conducted to determine the actual protein target (TWEAK or
Fn14). In regard to the second strategy, structures of the human
Fn14 extracellular domain (130, 131) and of the soluble TWEAK
trimer (in complex with the Fab fragment of a neutralizing mAb)
(132) have been determined via NMR and x-ray crystallography,
respectively. This information, in conjunction with TWEAK (131,
133) and Fn14 (131, 134) mutagenesis data and the available struc-
tures of several closely related TNF:TNFR superfamily member
complexes, has been used by three groups to derive molecular
models of the TWEAK:Fn14 complex (131–133). Dhruv et al.
(133) successfully utilized their validated model for the in sil-
ico identification of small molecule inhibitors of TWEAK:Fn14
binding. Briefly, 60 compounds scoring positive in the virtual
screen were obtained and rescreened for inhibitory activity using
an ELISA assay. Subsequent studies indicated that one of the com-
pounds, L524-0366, was a potent inhibitor of TWEAK-stimulated
NF-κB pathway activation and glioma cell migration in vitro. It
is anticipated that more small molecule drugs disrupting either
TWEAK:Fn14 binding or other critical protein-protein interac-
tions associated with this signaling node will be discovered in the
next few years.
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FIGURE 1 | Summary of the threeTWEAK/Fn14 axis-targeted
therapeutic strategies discussed in this review. (A) Four
TWEAK-neutralizing agents have been developed to prevent TWEAK:Fn14
engagement and thereby inhibit disease progression. (B) Three
Fn14-directed agonistic mAbs have been developed to activate Fn14
signaling in tumor cells and promote cell death. Studies have shown that
TWEAK-induced cell death in vitro is an indirect effect mediated by other
cytokines, so the anti-tumor efficacy of these agents may occur via this
mechanism as well as by ADCC. The agonistic activity of these mAbs is
potentiated by oligomerization with protein G or binding to Fcγ receptors.
BIIB036 and 18D1, but not PDL192, can also inhibit TWEAK:Fn14 binding.
(C) Three Fn14-directed agents have been developed that use Fn14 as a
portal to deliver toxins or pro-apoptotic proteins into tumor cells. All of the
agents shown in this figure have therapeutic efficacy in animal models, and
the three agents in bold type have been or are currently under investigation
in human clinical trials. Drawing adapted from Figure 3 in Ref. (135).
SUMMARY
The TWEAK/Fn14 axis was first described ~12 years ago, and
since that time studies from around the globe have revealed
that Fn14-triggered signal transduction and downstream cellu-
lar responses could potentially play a role in the pathophysiology
of many major human diseases, including cardiovascular disease,
stroke, and cancer. These studies have led to drug development
efforts and the first TWEAK- or Fn14-targeted therapeutic agents
(Figure 1). Three of these agents have already entered clinical trials,
and this is remarkable progress. However, only the collaborative
efforts of basic, translational and clinical researchers will continue
to move the TWEAK/Fn14 axis field forward in the coming years,
and it is anticipated that this research will ultimately lead to safe
and effective therapeutics for clinical use.
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